Bessemer Group’s Apellis Pharmaceuticals APLS Stock Holding History

Bessemer Group’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-205	Closed	-$5K	–	2489
2025 Q4	$5K	Buy	+205	New	+$4.81K	﹤0.01%	2243

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bessemer Group's APLS Position: Q1 2026 in Review

Bessemer Group sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 205 shares — an estimated $5K sold.

Bessemer Group first reported a position in APLS in Q4 2025 and held it in 1 quarter. The position peaked at $5K in Q4 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Bessemer Group reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bessemer Group sold 205 Apellis Pharmaceuticals shares in Q1 2026, an estimated $5K.
Bessemer Group first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Bessemer Group's Apellis Pharmaceuticals position peaked at $5K in Q4 2025.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.